Term ends Dec 21, 2035 · High confidence
20-year base term ends Dec 21, 2035
Dec 21, 2015
Dec 21, 2035
Feb 10, 2026
This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. 0 of 2 maintenance fees are paid so far. Confidence: High. from the record
How we calculated this date
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Dec 21, 2015, when application PCT/IB2015/059836, the earliest non-provisional in its chain, was filed (this one was filed Mar 24, 2025) | Dec 21, 2035 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 11,801,300, US 12,296,008, US 12,485,172, US 12,485,173, US 12,599,664) | resolves to Dec 21, 2035, no earlier than this term, so no change | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 0 of 2 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Dec 21, 2035 | High confidence |
This family
| US 11,801,300 | In force Dec 2035 | Dec 2035 |
| US 12,599,664 | In force Jan 2036 | Jan 2036 |
| US 12,296,008 | In force Dec 2035 | Dec 2035 |
| US 12,485,173 | In force Dec 2035 | Dec 2035 |
| US 12,485,172 | In force Dec 2035 | Dec 2035 |
| US 12,544,438 | this patent Dec 2035 | Dec 2035 |
| US 12,702,711 | In force Dec 2035 | Dec 2035 |
| US 12,741,024 | In force Dec 2035 | Dec 2035 |
Assignments
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Sep 13, 2025 Reel 72892, frame 26 | Serno-schersch, Kathrin | Novartis Pharma AG | Assignment of Assignor's Interest |
| Sep 13, 2025 Reel 72892, frame 44 | Novartis Pharma AG | Novartis AG | Assignment of Assignor's Interest |
| Jun 11, 2026 Reel 75712, frame 291 | Novartis AG | Novartis Pharma AG | Assignment of Assignor's Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
What's changing
A terminal disclaimer resolved from the filed document, referencing US 11,801,300, US 12,296,008, US 12,485,172, US 12,485,173, US 12,599,664, ends no earlier than this term, so it caps nothing.